Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 25, 2023

Safety of Diroximel Fumarate in Patients With Relapsing–Remitting MS

Multiple Sclerosis (Houndmills, Basingstoke, England)

 

Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
Mult. Scler. 2023 Oct 31;[EPub Ahead of Print], BA Singer, DL Arnold, J Drulovic, MS Freedman, R Gold, M Gudesblatt, E Jasinska, CC LaGanke, RT Naismith, D Negroski, J Oh, MA Hernandez Perez, K Selmaj, F Then Bergh, A Wundes, T Ziemssen, W Castro-Borrero, H Chen, S Levin, M Scaramozza, SL Shankar, T Wang, S Wray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading